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We  describe three cases of community-acquired necrotizing pneumonia which were caused
by  Panton–Valentine leucocidin-producing strains of Staphylococcus aureus (one of them
methicillin  sensitive). All cases were successfully treated without any sequelae for the
patients  due to the prompt initiation of adequate antimicrobial therapy. High suspicion
toward  this fatal pathogen was the key to the successful outcome of the patients.




suffering from pneumonia and severe respiratory distress. He
was transferred from another hospital where he presented
with  high fever, weakness and productive cough. He hadntroduction
ommunity-acquired pneumonia due to Staphylococcus aureus
s  an infrequent but potentially lethal infection.1,2 It is often
ssociated with the production of Panton–Valentine leuco-
idin  (PVL), which is responsible for extensive tissue necrosis
nd  a high mortality rate.3 Herein we present three cases of
ecrotizing  pneumonia, one of them caused by a methicillin
usceptible strain, all of which had a favorable outcome. The work was performed at Attikon University Hospital.
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Case  1
A previously healthy 18-year-old boy, a Panama resident trav-
eling  in Europe, was  admitted to the ICU of our hospitalital, Athens, Greece.
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i s . 2 0342  b r a z j i n f e c t d 
been hospitalized for three days and received oseltamivir,
ceftriaxone and moxiﬂoxacin. He reported having a ﬂu-like
syndrome some days earlier.
At ICU admission he had a temperature of 38 ◦C, a respi-
ratory rate of 40 per min, a heart rate of 120 beats/min and
he  was  hemodynamically stable. Thorax auscultation revealed
crackles  over the lower and middle, right lung ﬁelds, while
chest  X-ray (CXR) showed patchy alveolar opacities in the
right  lung. Blood gases on admission showed: pH 7.31, pCO2:
50  mmHg, pO2: 65 mmHg  in a non-rebreathing mask. Labora-
tory  ﬁndings revealed a white blood count (WBC) of 1220 cells/L
(59%  neutrophils) and a CRP of 306 mg/L. The Acute Phys-
iology  and Chronic Health Evaluation (APACHE) II severity
score  was  21. His respiratory distress gradually increased
and  24 h later he was  intubated and needed inotropic sup-
port.  The new CXR revealed that alveolar type inﬁltrates
were  spread in both lungs. Urine antigens for Legionella
pneumophila type 1 and Streptococcus pneumoniae were  nega-
tive.
A  bronchoscopy was  performed and the Gram stain of the
BAL  revealed the presence of numerous Gram-positive cocci.
The  treatment was  switched to linezolid and moxiﬂoxacin.
Cultures from BAL specimens yielded a PVL, methicillin sensi-
tive  S. aureus (MSSA) while blood cultures were  negative. Test
for  HIV was  negative.
Hydrocortisone was  added to the therapeutic regimen
because of the septic shock and ﬁlgrastim was  given for the
leukopenia.  Clindamycin was  also added in order to diminish
the  toxin production by the PVL strain.4
On day 8 the fever subsided but his course was  compli-
cated by a spontaneous pneumothorax, which necessitated
the  insertion of a pleural catheter. Subsequently he suffered
an  episode of bacteremic ventilator-associated pneumonia by
a carbapenem-resistant Klebsiella pneumoniae, which was suc-
cessfully treated with colistin and tigecycline. The patient was
extubated  on day 21 and he was  ﬁnally discharged on day
27.
Case  2
A 34-year-old woman  was  transferred to our ICU from the
Department  of Obstetrics and Gynecology due to severe respi-
ratory  failure six days after in vitro fertilization. She had
no  past medical history. The embryo-transfer was  compli-
cated  by Ovarian Hyperstimulation Syndrome. On admission
the  APACHE II score was  26 and blood gases values were
pH:  7.33, pO2: 80 mmHg, pCO2: 38 mmHg  on facemask pro-
viding  FiO2 of 40%. Auscultation revealed diffuse crackles.
During the next 6 h her temperature rose to 39.5 ◦C and she
presented  productive cough with dark sputum and short-
ness  of breath at rest, so she was  admitted to the ICU. CXR
on  ICU admission revealed an inﬁltrate of the left middle
lung  ﬁeld and bilateral pleural effusions. Laboratory tests
showed  a WBC  of 3700/L, CRP of 298 mg/L, procalcitonin of
36  ng/mL, ﬁbrinogen of 507 mg/dL, and hypogammaglobuli-
naemia, while human chorionic gonadotropin (hCG) levels
were  compatible with pregnancy. Sputum Gram stain revealed
Gram-positive cocci and urinary antigens for L. pneumophila
type  1, and S. pneumoniae and pharyngeal aspirate for Inﬂuen-
zae  A and B were  negative. Treatment with intravenous 1 4;1  8(3):341–345
linezolid and clindamycin was  immediately started because
the  severity of the patient’s condition and the isolation of
Gram-positive cocci in the sputum supported the clinical
suspicion of community-acquired staphylococcal pneumonia.
Nevertheless, the patient worsened and became hemody-
namically unstable requiring intubation and vasopressors.
She was  also given hydrocortisone and activated protein C.
The  blood cultures and the tracheal aspirate grew MRSA.
The  patient showed gradual hemodynamic improvement and
was  weaned from vasopressors after three days, while hCG
values  declined rapidly returning to nonpregnant range. A
chest  CT scan was  performed and showed bilateral inﬁltrates
with  multiple cavitating lesions, left lung abscess formation
and  bilateral pleural effusions. Culture of pleural ﬂuid devel-
oped  also MRSA. Her course was  complicated by nosocomial
bacteremia and she was  submitted to a tracheostomy. Gas
exchange  as well as lung mechanics gradually stabilized and
she  was ﬁnally weaned from mechanical ventilation. She was
discharged  to the ward on day 37 and she had a long rehabil-
itation  period.
Case  3
A 33-year-old male with no signiﬁcant past history was admit-
ted  to the ICU of our hospital because of acute respiratory
failure due to a lower respiratory tract infection. He pre-
sented  to the Emergency Department several days earlier
complaining for chest pain, high temperature (39 ◦C) and
progressive dyspnea with blood-stained sputum. The CXR
revealed  the presence of bilateral pulmonary inﬁltrates. After
his  admission to the internal medicine department his sit-
uation  progressively deteriorated and two days later he was
intubated  and transferred to the ICU. His treatment initially
included ceftriaxone and clarithromycin but because of the
severity  of his situation a staphylococcal pneumonia was  sus-
pected and the antibiotic regimen was empirically modiﬁed
to  linezolid and moxiﬂoxacin. On ICU admission he presented
hemodynamic instability and had to be resuscitated with
intravenous ﬂuids and norepinephrine. Initial laboratory data
obtained in the ICU showed WBC: 17.890/L (neutrophils: 82%),
CRP:  250 mg/L. Arterial blood gases analysis showed respira-
tory  acidosis and severe hypoxemia (pH: 7.11, pCO2: 91 mmHg,
pO2: 56 mmHg  – in assist control ventilation, FiO2: 100%). Blood
cultures  and sputum specimens taken in the ward  grew MRSA.
The  blood cultures remained positive after seven days of treat-
ment  with linezolid and daptomycin. Clindamycin were added
to  the regimen. Two transesophageal echos performed in ﬁf-
teen days time did not reveal the presence of vegetations.
Of  note, HIV and tests for other respiratory pathogens were
negative.
The  patient’s course was  complicated by the development
of  spontaneous pneumothorax and empyema  of the right lung
(Fig.  1). He had to be submitted to lung decortication. MRSA
was  also isolated from the culture of the pleural ﬂuid. On day
23  he was submitted to a tracheostomy. His situation amelio-
rated,  the tracheostomy was  closed and he was  transferred
to  the ward  on day 40. He was discharged from the hospital
one  month later. It should be noted that one of the herein
described cases has been previously published.5
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favorable  outcome.s well as bilateral consolidations and characteristic bullae.
n  vitro  evaluation  of  S.  aureus  clinical  isolates
even isolates were  available for further testing. Susceptibil-
ties  to various antimicrobial agents were  evaluated by an
utomated  system (BD Phoenix automated microbiology sys-
em; BD Diagnostic Systems, Sparks, MD)  (Table 1). All isolates
ere  found to carry the lukF-PV and lukS genes coding for
anton–Valentine leukocidin (PVL),6 while all isolates of cases
 and 3 were found to also carry the mecA gene in type IVc/e
taphylococcal cassette chromosome mec element (SCCmec).7
The PFGE patterns of SmaI-digested DNA of all isolates of
ases  2 and 3 were  identical. MLST typing performed only
o  blood isolates linked PFGE pattern with the well-described
T80 clone that seems to be spreading through Europe. Isolate
4442B  of case 1 was  lost to subculture and was  not submitted
o  MLST typing.
iscussion. aureus is a commonly recognized cause of infections in
umans.  These infections can become life-threatening due to
he ability of the microorganism to produce virulence factors
Table 1 – Minimum inhibitory concentrations (MICs) of 15 antim
Case Isolate no Source P OX FOX VA TEC 
1 m 4442 B BAL >1 0.5 ≤2 ≤1 ≤1 
2 SP  8728 Sputum >1 >2 >8 ≤1 ≤1 
SP 8753 Tracheal aspirate >1 >2 >8 ≤1 ≤1 
P 6538 Pleural-ﬂuid >1 >2 >8 ≤1 ≤1 
b 8503 Blood >1 >2 >8 ≤1 ≤1 
3 b  3286 Blood 1 2 8 ≤1 ≤1 
m 2332 Pleural-ﬂuid 1 1 4 ≤1 ≤1 4;1 8(3):341–345  343
including adhesion factors and toxins. PVL is a toxin produced
by  S. aureus strains (carrying the lukS-PV and lukF-PV genes)
often  associated to severe skin and soft tissue infections but
also  causing necrotizing pneumonia with a high mortality. The
presence  of this toxin has been detected among MRSA as well
as  MSSA strains.
The  usual patient with PVL-associated S. aureus pneumonia
is  a child or a young otherwise healthy adult. A viral illness can
precede  pneumonia while leucopenia attributed to the toxin
is  not an uncommon ﬁnding. A speciﬁc disease entity has
also  been ascribed to PVL-positive S. aureus-associated respi-
ratory  infection including a rapidly progressing hemorrhagic
and  necrotic pneumonia which can cause Acute Respiratory
Distress Syndrome (ARDS) possibly leading to septic shock and
multi-organ  failure.
We  describe three patients with severe pneumonia caused
by  Panton–Valentine-producing S. aureus. In two cases bac-
teremia  was  also present. Diagnosis of inﬂuenza was  not
conﬁrmed  in any case while prodrome ﬂu-like symptoms were
present in only one patient. Both MRSA isolates belonged
to  ST80, which is the most common clone causing infec-
tion  in the community as well as in the hospital in Greece.8
Among bloodstream infections caused by MRSA, the hospital-
associated  clone ST239 and sporadic cases of ST30, ST97 and
ST3989 follow ST80. One of the study isolates was  MSSA pro-
ducing  PVL. Although rare, the production of PVL toxin by
MSSA  strains has been reported previously.6
Three similar cases due to MRSA strains have also
been described in Greece, two of them with an unfavor-
able outcome.10,11 The mortality of PVL-positive CAP lies
between 45% and 56%.7,8 The severity of the disease is sim-
ilar  whether the isolate is a methicillin-resistant strain or not
because  it is associated to other factors such as multi-organ
failure, ICU admission, mechanical ventilation, leukopenia,
necrotizing pneumonia, shock, disseminated intravascular
coagulation, rash, ARDS, airway bleeding and development of
complications.12,13
Our patients presented some of these factors such as ICU
treatment, mechanical ventilation due to pneumonia-induced
ARDS and need for inotropic support while all of them devel-
oped  several complications. Two cases had leucopenia on
admission,  which is considered to be inversely associated with
survival.  On the contrary, another unfavorable prognostic fac-
tor, airway bleeding, was  absent possibly contributing to theThe  optimal treatment of this often lethal disease has not
been  established. Since the detrimental effects of the infec-
tion  are mainly caused by the production of PVL rather than
icrobials against S. aureus study isolates.
GM E CIP LVX CC SXT RA SYN LZD FA
≤2 0.5 ≤0.5 ≤1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 2 ≤2
≤2 >4 ≤0.5 ≤1 >2 ≤0.5 ≤0.5 ≤0.5 2 4
≤2 >4 ≤0.5 ≤1 >2 ≤0.5 ≤0.5 1 2 8
≤2 >4 ≤0.5 ≤1 >2 ≤0.5 ≤0.5 1 2 8
≤2 >4 ≤0.5 ≤1 >2 ≤0.5 ≤0.5 1 2 >8
≤2 ≤0.25 ≤0.5 ≤1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 2 4
≤2 ≤0.25 ≤0.5 ≤1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 2 4
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the microorganism itself, an effective treatment should target
ﬁrst  at the eradication of S. aureus but additionally at dimin-
ishing  the effects of the toxin. Drainage of the suppurative
collection, if possible, is suggested in order to remove PVL con-
taining  tissues. Furthermore certain antimicrobial agents are
able to reduce the production of PVL. Such molecules include
clindamycin, linezolid and rifampicin.14 These antimicrobial
agents are effective in reducing PVL production even at sub-
optimal  concentrations in necrotic tissues. Dumitresku et al.
have shown that if other agents such as beta-lactams are used
and  levels above the MIC  (minimum inhibitory concentrations)
are  not achieved in the infected tissues, PVL secretion may
be  enhanced.14 Moreover upregulation of PVL toxin observed
with  nafcillin15 could also result with ﬂucloxacillin when used
for  treating MSSA.16 As for clindamycin additional advan-
tages  of the drug include its ability (a) to decrease Toxic Shock
Syndrome  Toxin-1 production17 and (b) to stop production
of  alpha-toxin by translational inhibition.18 Combined use of
clindamycin  and linezolid has been described as having suc-
cessful  results on PVL toxin and patients’ survival in two of
three  cases of necrotizing pneumonia.19 On the other hand
vancomycin, a traditional drug for the treatment of MRSA,
has  no impact on exotoxin formation.20 Polyvalent human
intravenous immunoglobulin (IVIg) is an adjunctive therapy
for  serious PVL-associated infections. It acts by neutralizing
the  PVL pore formation and by inhibiting the cytotoxic effects
of  PVL on polymorphonuclear cells as shown by Gauduchon
et  al.21 Although the result appears to be dose-dependent, the
usually  reported dose does not exceed 2 g/kg.16 The use of IVIg
has  been reported to have a beneﬁt on patients’ survival in
sporadic  cases.19,22,23
All our patients received a combination of linezolid and
clindamycin agents that provide both antimicrobial action
and  anti-toxin effect. In the second case we used IVIg as
adjunctive therapy, a factor probably contributing to patients
recovery.  Of note, although the use of linezolid is only recom-
mended  for hospital-acquired MRSA pneumonia, it has the
advantage  of achieving high concentrations in the epithelial
lining  ﬂuid of the lung24 and it is a reasonable ﬁrst choice for
community-acquired MRSA pneumonia as well, particularly
in  the suspicion of PVL for the aforementioned reasons.
Panton–Valentine associated pneumonia remains a disease
entity  with a high fatality rate. A high degree of awareness is
necessary in order to initiate a proper and aggressive treat-
ment  even in the absence of a preceding ﬂu-like syndrome. As
the identiﬁcation of the toxin is not always feasible or quickly
performed, empirical choice of antimicrobials is of paramount
importance.
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